Anika Therapeutics Inc
ANIK
NASDAQ
Biotechnology
$21.50
USD
+0.33 (+1.56%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $286.13M
Volume 124.9K
About Anika Therapeutics Inc
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
CEO
Mr. Stephen Griffin
HQ
Bedford, MASSACHUSETTS, US
Founded
1985
Employees
235
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on ANIK.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
5.3%
+25.9 pp
Gross Margin (TTM)
62.2%
+4.9 pp
Operating Margin (TTM)
-4.2%
+3.8 pp
Net Margin (TTM)
-3.1%
+49.8 pp
ROE (TTM)
-2.8%
+38.3 pp
Free Cash Flow (TTM)
$562,000
—
Financial Snapshot
Revenue
$120.65M
+5.3%
YoY
Gross Margin
62%
TTM
+8.6%
YoY
Net Income
$-3.78M
+93.8%
YoY
Operating Cash Flow
$5.98M
-4.8%
YoY
Key Statistics
Open
$21.17
Previous Close
$21.17
Day Range
$21.04 - $21.98
52 Week Range
$8.22 - $22.88
Volume
124.9K
Average Volume (10 Days)
150.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$286.13M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
2.37
Price / Book
2.08
Financial Highlights
Profit Margin
-3.1%
Return on Assets
-2.1%
Return on Equity
-2.8%
Revenue (TTM)
$120.65M
Net Income (TTM)
$-3.78M
Diluted EPS (TTM)
-$0.27
Total Cash (MRQ)
$38.41M
Levered FCF (TTM)
$562,000
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
SION
Sionna Therapeutics Inc
$6.46
▼ -1.2%
AVXL
Anavex Life Sciences Corp
$3.22
▼ -1.5%
FATE
Fate Therapeutics Inc
$2.57
▲ +2.0%
IRD
Opus Genetics Inc
$3.61
▼ -3.0%
SRZN
Surrozen Inc
$23.96
▲ +1.0%
MYGN
Myriad Genetics Inc
$3.03
▼ -4.4%
TRDA
Entrada Therapeutics Inc
$7.46
▲ +0.1%
ALXO
ALX Oncology Holdings Inc
$1.96
▲ +1.0%
ZSQR
Z Squared Inc (Delaware)
$3.94
▼ -5.3%
ELDN
Eledon Pharmaceuticals Inc
$3.54
▼ -4.3%
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 03
Est. EPS
Adjusted consensus estimate
$0.05